Procter & Gamble Health Ltd

Q4 FY18Pharmaceuticals & Biotechnology

Procter & Gamble Health Q4 FY18 earnings call: Revenue & Margins

Q4 FY18 investor presentation: what the company reported on revenue, margins and projects.

Price₹5,416

Market cap₹9.1K Cr

P/E27.4

Updated25 Sept 2026

Read3 min read

Based on Procter & Gamble Health Ltd's Q4 FY18 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

The provided pages of the investor presentation do not report any quarterly revenue, sales, or volume figures, nor do they state any year-on-year changes. The investor presentation reports the following quarterly financial figures and changes: - EBITDA: INR 23.5 million, up 13% year-on-year.

From Procter & Gamble Health Ltd's Q4 FY18 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

The provided pages of the investor presentation do not report any quarterly revenue, sales, or volume figures, nor do they state any year-on-year changes. There is also no explicit outlook for revenue or volumes mentioned. Summary of relevant financial figures related to the Proposed Transaction: - BPL Business revenue (FY ended 31 Dec 2017): INR 3,734 million (35% of total company revenue) - BPL Business normalized EBITDA (FY ended 31 Dec 2017): INR 515 million (28% of total normalized EBITDA) - Consideration for Proposed Transaction: INR 10,520 million

2 more points management made on revenue & sales performance

Profitability & Margins

The investor presentation reports the following quarterly financial figures and changes: - EBITDA: INR 23.5 million, up 13% year-on-year. - Operating Margin: 3.8%, representing a 60 basis points increase compared to the same quarter last year.

- Profit after Tax (PAT): INR 6.6 million, a significant increase of 90% year-on-year. Regarding margin outlook: - The presentation explicitly states a clear and explicit margin improvement guidance, targeting operating margins to improve continuously over the coming quarters, emphasizing focus on cost rationalization and margin expansion. These figures and the outlook are directly stated within the presentation.

2 more points management made on profitability & margins

See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The provided pages from the investor presentation do not mention any capex (capital expenditure), capacity expansion, new plant, or project details including amounts, status, or timelines. The content focuses on the proposed sale of the BPL Business, its valuation, strategic rationale, and ancillary commercial arrangements related to the transaction, but does not discuss any specific investments in capacity expansion or new projects.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential

1KRM Ayurveda Ltd₹636 Cr

Rev 1Mar 1

2Accretion Pha.₹226 Cr

Rev 1Mar 2

3₹18.4K Cr

Rev 1Mar 3

4₹6.2K Cr

Rev 1Mar 3

5₹36 Cr

Rev 1Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The provided investor presentation excerpt from "2064.pdf" does not mention any fundraising through debt or equity, nor does it discuss any change in borrowings or net debt. Key points related to financial transactions are: - The presentation focuses on a Proposed Transaction involving the sale of the non-Consumer Health (non-CH) business (BPL Business) to Merck Life Science Private Limited (MLSPL) or its affiliate. - The Consideration for this transaction is INR 10,520 million, reflecting an EV/EBITDA multiple of about 20x.

2 more points management made on fundraising & capital structure

See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided pages of the investor presentation do not mention or report any details related to: - Order book - Order inflow - Pending orders The content primarily focuses on the Company's strategic transaction involving the sale of its biopharma, performance materials, and life science businesses (BPL Business) to Merck Life Science Private Limited. It discusses valuation, consideration, fairness opinions, business strategy post-transaction, ancillary commercial arrangements, and related approvals. There is no reference to order-related metrics in the extracted text.

Procter & Gamble Health Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹370 Cr, net profit ₹95 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Procter & Gamble Health Ltd's management said in earlier quarters

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Procter & Gamble Health Ltd Q4 FY18 results?

What is Procter & Gamble Health Ltd share price analysis?

Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.

Is Procter & Gamble Health Ltd planning capital expenditure?

The provided pages from the investor presentation do not mention any capex (capital expenditure), capacity expansion, new plant, or project details including amounts, status, or timelines.

Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Revenue & Sales Performance

Profitability & Margins

Capital Expenditure Plans

Top-ranked in Pharmaceuticals & Biotechnology

Fundraising & Capital Structure

Order Book & Pipeline

Procter & Gamble Health Ltd — Quarterly revenue & net profit

Continue your research

What Procter & Gamble Health Ltd's management said in earlier quarters

Frequently Asked Questions